ISIS Pharmaceuticals Inc.

ISIS Pharmaceuticals Inc. announced that it will receive $4.6 million dollars from Alnylam Pharmaceuticals, Inc. as its portion of the upfront fees in the recently announced transaction between Takeda Pharmaceutical Company Limited and Alnylam. In addition, Isis has the potential to receive portions of future milestone and royalty payments. This transaction further emphasizes the value of Isis' innovation and the leadership role Isis has played in the field of nucleic acid based therapeutics. Isis owns or controls more than 1,500 issued patents, through which it has generated well over $100 million in licensing fees.